{
    "nct_id": "NCT03383458",
    "official_title": "A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation",
    "inclusion_criteria": "* Participants with a first diagnosis of HCC who have undergone a curative resection or ablation\n* Participants are eligible to enroll if they have non-viral related-HCC, or if they have HBV-HCC, or HCV-HCC\n* Child-Pugh Score 5 or 6\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC\n* Any evidence of tumor metastasis or co-existing malignant disease\n* Participants previously receiving any prior therapy for HCC, including loco-regional therapies\n* Participants who have undergone a liver transplant or those who are in the waiting list for liver transplantation\n* Participants who have received a live/attenuated vaccine within 30 days of randomization (eg, varicella, zoster, yellow fever, rotavirus, oral polio and measles, mumps, rubella [MMR]).\n\nOther protocol defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}